• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is ImmunityBio (IBRX) A Bargain As Turkey Expansion Fuels Fresh Growth Hopes?

    Simply Wall St·09/25/2026 09:25:32
    Listen to the news

    ImmunityBio (IBRX) moved back into focus after its shares climbed nearly 10% following founder Dr. Patrick Soon-Shiong’s high-profile meeting with Turkish President Recep Tayyip Erdogan. The meeting highlighted planned expansion into Turkey’s cancer care market.

    For context, ImmunityBio’s share price is now at US$8.64, with a year-to-date share price return of 327.72% and a 1-year total shareholder return of 251.22%, while the recent 90-day share price return slipped 0.80%, hinting that momentum has cooled a little even as news such as the Turkey expansion keeps optimism alive around execution and risk.

    Spot opportunities riding similar healthcare catalysts by scanning our curated list of 38 healthcare AI stocks alongside ImmunityBio’s latest move into Turkey’s cancer care market.

    ImmunityBio now blends an FDA approved therapy, fresh international expansion headlines, and a roughly US$9.1b market value. The real tension is simple: Are you paying a fair price for that story today?

    Most Popular Narrative: 34% Undervalued

    ImmunityBio’s most followed valuation storyline pegs fair value at $13 per share, well above the last close at $8.64. This comparison puts the current price against some very ambitious expectations for its cancer and immunology pipeline.

    The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time. This expansion is directly tied to expectations for future product revenue growth.

    The broad use of checkpoint inhibitors across many tumor types has created a large pool of patients with limited options after checkpoint failure. ANKTIVA combinations targeting this setting, such as in QUILT-3.055, address an existing treatment gap that could influence future revenue and potentially support higher utilization per patient.

    See why 14 investors see ImmunityBio as 34% undervalued.

    Result: Fair Value of $13 (UNDERVALUED)

    Still, ImmunityBio’s story can break if ANKTIVA trials disappoint or if regulators and payers prove tougher than the current narrative quietly assumes.

    Find out about the key risks to this ImmunityBio narrative.

    Next Steps

    Mixed signals around ImmunityBio and ANKTIVA can feel exciting or worrying in equal measure. Move quickly, review the underlying data, and weigh both sides through the 3 key rewards and 1 important warning sign.

    Looking for more ImmunityBio sized ideas?

    Do not stop with ImmunityBio. Broaden your watchlist with fresh ideas that match your risk profile, income goals, and appetite for mispriced opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.